Understanding bronchiectasis, one patient at a time.
INBARC is a nationwide study following 300 adults with bronchiectasis at 20 hospitals across India for two years — to understand the condition better and improve how it is treated.
A NATIONAL RESEARCH NETWORK
WHAT WE STUDY
A condition that's under-researched, and under-recognised.
Bronchiectasis is a long-term lung condition in which the airways become widened and damaged, leading to repeated infections, persistent cough and long-term breathing difficulty. It is becoming more common worldwide — yet in India it remains understudied.
The Indian pattern is different: it is very often linked to past tuberculosis (TB), unlike in Western countries. INBARC will build India’s largest, most detailed dataset on bronchiectasis to guide diagnosis and treatment.
Read more about INBARC →WHO IT'S FOR
Built for everyone in the care pathway.
Whether you're living with bronchiectasis, treating it, or studying it — the registry is designed around your role.
For patients
Adults with confirmed bronchiectasis can be enrolled through a participating hospital and followed over 24 months, with clear, scheduled visits.
For clinicians
Identify eligible patients, enrol them at a participating site, and join a national network of pulmonologists studying the same condition.
For researchers
Contribute to a detailed, standardised dataset on causes, outcomes and risk in Indian patients — built across 20 hospitals.
THE PATIENT JOURNEY
24 months, four planned visits.
Screening
Eligibility is checked and written informed consent is taken.
Baseline · Month 0
Visit 1: history, breathing tests, questionnaires, blood and sputum samples.
Follow-up · Months 6 & 12
Visits 2 and 3 track lung function, symptoms and quality of life.
Final visit · Month 24
Visit 4 is the final visit, with a repeat HRCT chest scan.
Plus: whenever a participant has a flare-up, an extra visit is done within 72 hours. See the full visit schedule →
WHAT WE'RE TRYING TO FIND OUT
Five main study objectives.
Find the causes
Identify why bronchiectasis develops in Indian patients — TB, allergy, infection and more.
Track over time
Follow lung function, symptoms and quality of life across 24 months.
Compare infection tests
Compare standard sputum culture with newer rapid PCR technology.
Identify patient groups
Find an “allergic” (eosinophilic) subgroup that may respond to targeted therapy.
Predict risk
Build and validate a scoring tool to predict which patients are at higher risk.
SUPPORTED BY